A year ago, MSD and Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) was rejected by ...

Axtria’s flagship event is almost here! Axtria Ignite 2025 is taking place 4th to 5th June at the Princeton Marriott at ...

The PMCPA also agreed with the complainant that Pfizer had not taken all possible steps to avoid similar breaches in its ...

The award from the Biomedical Advanced Research and Development Authority (BARDA), part of the US Department of Health and ...

In a second piece of good news in the development of new antimicrobials this week, GSK has said it will file its oral ...

The verdict of the US district court in New Jersey is that Shilpa's generic infringes a US patent on multikinase inhibitor ...

Beleaguered Biogen has been handed some encouraging news from the FDA, after the regulator agreed to complete its review of amyotrophic lateral sclerosis (ALS) therapy tofersen within six months.

UK biotech F2G has raised $100 million as it prepares to refile its olorofim candidate for invasive fungal infections, which was turned down last year by the FDA. The Manchester-based company said ...

It’s no secret that challenges related to misinformation are rising, as more people rely on personalised news feeds and non-traditional information channels across the internet and social media ...

Bristol-Myers Squibb has signed another deal to build its capabilities in antibody-drug conjugates for cancer, paying $100 million upfront to take control of an Orum Therapeutics candidate with a ...

As the buzz increases in volume and the clock to kick-off counts down, keep an eye on this Spotlight On page for content ...

Treatment of PG is currently limited to immune-suppressing drugs and antibiotics to treat complicating infections, and, in ...